IL161378A0 - Treatment of acute myeloid leukemia with indolinone compounds - Google Patents
Treatment of acute myeloid leukemia with indolinone compoundsInfo
- Publication number
- IL161378A0 IL161378A0 IL16137802A IL16137802A IL161378A0 IL 161378 A0 IL161378 A0 IL 161378A0 IL 16137802 A IL16137802 A IL 16137802A IL 16137802 A IL16137802 A IL 16137802A IL 161378 A0 IL161378 A0 IL 161378A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- myeloid leukemia
- acute myeloid
- indolinone compounds
- indolinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33062301P | 2001-10-26 | 2001-10-26 | |
| PCT/US2002/034525 WO2003035009A2 (en) | 2001-10-26 | 2002-10-28 | Treatment of acute myeloid leukemia with indolinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161378A0 true IL161378A0 (en) | 2004-09-27 |
Family
ID=23290562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16137802A IL161378A0 (en) | 2001-10-26 | 2002-10-28 | Treatment of acute myeloid leukemia with indolinone compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20030130280A1 (zh) |
| EP (1) | EP1446117A4 (zh) |
| JP (1) | JP2005511540A (zh) |
| KR (1) | KR20040062591A (zh) |
| CN (1) | CN101052394A (zh) |
| AU (1) | AU2002360314B2 (zh) |
| BR (1) | BR0213960A (zh) |
| CA (1) | CA2464790A1 (zh) |
| CZ (1) | CZ2004619A3 (zh) |
| HU (1) | HUP0500422A3 (zh) |
| IL (1) | IL161378A0 (zh) |
| IS (1) | IS7222A (zh) |
| MX (1) | MXPA04003853A (zh) |
| NZ (1) | NZ532405A (zh) |
| PL (1) | PL370553A1 (zh) |
| TN (1) | TNSN04065A1 (zh) |
| TW (1) | TWI259081B (zh) |
| WO (1) | WO2003035009A2 (zh) |
| ZA (1) | ZA200403091B (zh) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100657110B1 (ko) | 2002-02-15 | 2006-12-12 | 파마시아 앤드 업존 캄파니 엘엘씨 | 인돌리논 유도체의 제조방법 |
| US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| TW200418836A (en) † | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
| US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
| MXPA06003661A (es) * | 2003-10-02 | 2006-06-05 | Pharmacia & Upjohn Co Llc | Sales y polimorfos de un compuesto de indolinona sustituido con pirrol. |
| US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
| US20080193448A1 (en) * | 2005-05-12 | 2008-08-14 | Pfizer Inc. | Combinations and Methods of Using an Indolinone Compound |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| EP1928462A1 (en) * | 2005-09-20 | 2008-06-11 | Pfizer Products Incorporated | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| EP1926725A4 (en) * | 2005-09-22 | 2010-10-06 | Scripps Research Inst | PROTEIN KINASEINHIBITORS ON ALKOXYINDOLINONE BASE |
| KR101443651B1 (ko) | 2005-10-18 | 2014-09-23 | 얀센 파마슈티카 엔.브이. | Ｆｌｔ-3 키나제의 억제 방법 |
| JP5256047B2 (ja) * | 2006-01-27 | 2013-08-07 | シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド | ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤 |
| JP5331680B2 (ja) | 2006-04-20 | 2013-10-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ｃ−ｆｍｓキナーゼの阻害剤 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| AU2007240437B2 (en) | 2006-04-20 | 2012-12-06 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
| US8084621B2 (en) | 2006-12-04 | 2011-12-27 | Jiangsu Simcere Pharmaceutical R&D Co. Ltd. | 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| WO2009100929A1 (en) * | 2008-02-13 | 2009-08-20 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
| EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2098521A1 (en) | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
| EP2313396A1 (en) | 2008-06-23 | 2011-04-27 | Natco Pharma Limited | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt |
| EP2138167A1 (en) * | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
| EP2264027A1 (en) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| WO2011083124A1 (en) | 2010-01-05 | 2011-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
| US8962665B2 (en) | 2010-01-12 | 2015-02-24 | Ab Science | Thiazole and oxazole kinase inhibitors |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| EP2654799B1 (en) | 2010-12-23 | 2017-11-08 | Nektar Therapeutics | Polymer-sunitinib conjugates |
| WO2012088522A1 (en) | 2010-12-23 | 2012-06-28 | Nektar Therapeutics | Polymer-des-ethyl sunitinib conjugates |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| AU2013299922B2 (en) | 2012-08-07 | 2018-06-21 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
| KR101738063B1 (ko) | 2012-09-21 | 2017-05-19 | 아로그 파마슈티칼스, 인코퍼레이티드 | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2014100734A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| CN103274986A (zh) * | 2013-06-20 | 2013-09-04 | 湖南欧亚生物有限公司 | 一种舒尼替尼中间体的合成和精制方法 |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| WO2016016370A1 (en) | 2014-07-31 | 2016-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists |
| EP3177288A4 (en) | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| JP2019532011A (ja) | 2016-11-02 | 2019-11-07 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| WO2018211018A1 (en) | 2017-05-17 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 inhibitors for improving pain treatments by opioids |
| WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| US11713310B2 (en) | 2020-07-20 | 2023-08-01 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287132B6 (sk) * | 1998-05-29 | 2009-12-07 | Sugen, Inc. | Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu |
| WO2001045689A2 (en) * | 1999-12-22 | 2001-06-28 | Sugen, Inc. | Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| DE122010000004I1 (de) * | 2000-02-15 | 2010-04-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| JP2004518669A (ja) * | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | ４−アリール置換インドリノン |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| EP1434774A1 (en) * | 2001-10-10 | 2004-07-07 | Sugen, Inc. | 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
-
2002
- 2002-10-25 TW TW091125049A patent/TWI259081B/zh not_active IP Right Cessation
- 2002-10-28 AU AU2002360314A patent/AU2002360314B2/en not_active Ceased
- 2002-10-28 CZ CZ2004619A patent/CZ2004619A3/cs unknown
- 2002-10-28 JP JP2003537578A patent/JP2005511540A/ja not_active Withdrawn
- 2002-10-28 CN CNA028229592A patent/CN101052394A/zh active Pending
- 2002-10-28 US US10/281,266 patent/US20030130280A1/en not_active Abandoned
- 2002-10-28 CA CA002464790A patent/CA2464790A1/en not_active Abandoned
- 2002-10-28 NZ NZ532405A patent/NZ532405A/en unknown
- 2002-10-28 IL IL16137802A patent/IL161378A0/xx unknown
- 2002-10-28 WO PCT/US2002/034525 patent/WO2003035009A2/en active IP Right Grant
- 2002-10-28 PL PL02370553A patent/PL370553A1/xx not_active Application Discontinuation
- 2002-10-28 BR BR0213960-0A patent/BR0213960A/pt not_active IP Right Cessation
- 2002-10-28 EP EP02795563A patent/EP1446117A4/en not_active Withdrawn
- 2002-10-28 MX MXPA04003853A patent/MXPA04003853A/es not_active Application Discontinuation
- 2002-10-28 HU HU0500422A patent/HUP0500422A3/hu unknown
- 2002-10-28 KR KR10-2004-7006222A patent/KR20040062591A/ko not_active Application Discontinuation
-
2004
- 2004-04-15 IS IS7222A patent/IS7222A/is unknown
- 2004-04-16 TN TNP2004000065A patent/TNSN04065A1/en unknown
- 2004-04-22 ZA ZA200403091A patent/ZA200403091B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0500422A2 (hu) | 2005-11-28 |
| BR0213960A (pt) | 2004-08-31 |
| EP1446117A4 (en) | 2008-01-23 |
| ZA200403091B (en) | 2005-01-14 |
| MXPA04003853A (es) | 2005-02-17 |
| PL370553A1 (en) | 2005-05-30 |
| KR20040062591A (ko) | 2004-07-07 |
| CA2464790A1 (en) | 2003-05-01 |
| US20030130280A1 (en) | 2003-07-10 |
| CN101052394A (zh) | 2007-10-10 |
| IS7222A (is) | 2004-04-15 |
| CZ2004619A3 (cs) | 2005-03-16 |
| WO2003035009A2 (en) | 2003-05-01 |
| HUP0500422A3 (en) | 2009-09-28 |
| JP2005511540A (ja) | 2005-04-28 |
| AU2002360314B2 (en) | 2007-09-20 |
| NZ532405A (en) | 2005-12-23 |
| EP1446117A2 (en) | 2004-08-18 |
| TWI259081B (en) | 2006-08-01 |
| TNSN04065A1 (en) | 2006-06-01 |
| WO2003035009A3 (en) | 2004-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161378A0 (en) | Treatment of acute myeloid leukemia with indolinone compounds | |
| ZA200305691B (en) | The use of substituted azetidione compounds for the treatment of sitosterolemia | |
| EP1578446A4 (en) | ANTI-CD33 ANTIBODIES AND METHOD OF TREATING ACUTE MYELOID LEUKEMIA USING THE SAME | |
| IL157425A0 (en) | Treatment of solid tumours with paramycin derivatives | |
| PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
| IL161511A0 (en) | Therapeutic isoquinoline compounds | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| IL161509A0 (en) | Therapeutic quinolone compounds with 5-ht-antogonistic properties | |
| IL161597A0 (en) | Therapeutic quinoline compounds with 5-ht-antagonistic properties | |
| PL377464A1 (pl) | Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN | |
| PL378762A1 (pl) | Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi | |
| AU8322401A (en) | Indole compounds useful for the treatment of cancer | |
| HU0103986D0 (en) | New compounds with therapeutic effect | |
| EP1461030A4 (en) | AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | |
| HUP0402341A3 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| AU2002364711A8 (en) | Substituted 5-hydroxy-indole compounds for the treatment of glaucoma | |
| GB0103031D0 (en) | Novel treatment | |
| AU2003301905A8 (en) | Compositions and methods for treating acute myeloid leukemia | |
| SI1485352T1 (en) | Azaspiro compounds for the treatment of pain | |
| EP1453529A4 (en) | TREATMENT OF SEPSIS WITH TAFI | |
| AU2002341485A1 (en) | Treatment of polyaluminium compounds | |
| SI1485057T1 (sl) | Derivati azaspiro spojin za zdravljenje bolecine | |
| GB0120654D0 (en) | Treatment of anemia | |
| GB0120406D0 (en) | Treatment of anemia | |
| GB0100599D0 (en) | Therapeutic compounds |